Metabolizable alloy clusters assemble nanoinhibitor for enhanced radiotherapy of tumor by hypoxia alleviation and intracellular PD-L1 restraint DOI Creative Commons

Guanwen Ding,

Shengnan Liu, Xiangshan Yang

et al.

Journal of Nanobiotechnology, Journal Year: 2024, Volume and Issue: 22(1)

Published: Dec. 19, 2024

Cancer radiotherapy (RT) still has limited clinical success because of the obstacles including radioresistance hypoxic tumors, high-dose X-ray–induced damage to adjacent healthy tissue, and DNA-damage repair by intracellular PD-L1 in tumor. Therefore, overcome these multifunctional core–shell BMS@Pt2Au4 nanoparticles (NPs) are prepared using nanoprecipitation followed electrostatic assembly. Pt2Au4 clusters released from NPs alleviate tumor hypoxia catalyzing decomposition endogenous H2O2 generate O2 as well enhancing X-ray deposition at site, which thereby reduce required dose. The BMS-202 molecules simultaneously blockade on cells, causing activation effector T cells inhibition repair. Consequently, based enhance expression calreticulin cancer transposition HMGB1 nucleus cytoplasm, generation reactive oxygen species (ROS), DNA breakage apoptosis vitro. rate reached 92.5% under three cycles 1-Gy irradiation vivo. In conclusion, therapeutic outcome supports high-efficiency tumors expressing PD-L1.

Language: Английский

Catalase-Knockout Complements the Radio-Sensitization Effect of Titanium Peroxide Nanoparticles on Pancreatic Cancer Cells DOI Creative Commons
Winda Tasia,

Amane Washio,

Koki Yamate

et al.

Molecules, Journal Year: 2025, Volume and Issue: 30(3), P. 629 - 629

Published: Jan. 31, 2025

In previous studies, titanium peroxide nanoparticles (PAA-TiOx NPs) with surfaces functionalized using polyacrylic acid (PAA) and hydrogen (H2O2) demonstrated a synergistic effect when combined X-ray irradiation. The combination generated H2O2 reactive oxygen species (ROS) that enhanced the irradiation efficacy. present study, we examined relationship between catalase PAA-TiOx NPs sensitization to radiation because is primary antioxidant enzyme converts water oxygen. Catalase-knockout PANC-1 (dCAT) cells were CRISPR/Cas9 system, which was confirmed by suppression of expression in mRNA protein levels resulted an 81.7% decrease activity compared wild-type cells. Catalase deficiency found increase production ROS, particularly hypoxia. Also, 5 Gy 7-fold survival fraction (SF; p < 0.01) dCAT rates documented Interestingly, treatment 3 SF similar observed treated same but at higher dose (5 Gy). These results suggest strategy inhibition could be used establish advanced for pancreatic cancer

Language: Английский

Citations

0
An aggregation-induced emission-active lysosome hijacker: sabotaging lysosomes to boost photodynamic therapy efficacy and conquer tumor therapeutic resistance DOI Creative Commons

Hang Zou,

Pingping Wang, Zhihao Bai

et al.

Materials Today Bio, Journal Year: 2025, Volume and Issue: 31, P. 101564 - 101564

Published: Feb. 8, 2025

Therapeutic resistance is a major challenge in clinical cancer theranostics, often leading to treatment failure and increased patient mortality. Breaking this therapeutic deadlock, enhancing the efficacy of treatments, ultimately improving survival rates are both highly desirable significantly challenging goals. Herein, we have developed new fluorescent luminogen, QM-DMAC, which features aggregation-induced emission (AIE), exceptional viscosity-responsive properties. The AIE-active QM-DMAC can specifically stain lysosomes tumor cells, offering high signal-to-noise ratio enabling specific visualization variations lysosomal viscosity, such as those induced by inflammation or autophagy. Furthermore, effectively generates reactive oxygen species (ROS) under white light irradiation, precisely induces ROS-mediated membrane permeabilization (LMP) lysosome rupture. This causes severe cell damage restores sensitivity cells radiotherapy chemotherapy. Thus, serves efficient lysosome-targeting photosensitizer an excellent sensitizer. innovative "lysosome hijacking" strategy maximizes photodynamic therapy, conquering boosting synergistic effect when integrated with conventional It provides novel approach design theranostic agents for theranostics.

Language: Английский

Citations

0
Harnessing the power of traceable system C-GAP: homologous-targeting to fire up T-cell immune responses with low-dose irradiation DOI Creative Commons

Weijie Zhuang,

Kuangwu Pan,

Jie Wu

et al.

Journal of Nanobiotechnology, Journal Year: 2025, Volume and Issue: 23(1)

Published: March 12, 2025

While radiotherapy-induced immunogenic cell death (ICD) holds potential for enhancing cancer immunotherapy, the conventional high-dose irradiation often leads to an immunosuppressive microenvironment and systemic toxicity. Therefore, a biomimetic nanoplatform membrane coated-nitrogen-doped graphene quantum dots combined with Au nanoparticles (C-GAP) was developed in this study. Firstly, homologous traceable targeting features of C-GAP enables tumor-selective accumulation, providing reference selection timing radiotherapy. Secondly, radiosensitization by Low-dose (LDI) amplifies reactive oxygen species (ROS) generation trigger potent ICD. Thirdly, remarkable immune remodeling induced enhances CD8+ T infiltration effector function. Single-cell RNA sequencing revealed that C-GAP-LDI combination upregulates TNF CCL signaling pathway expression tumor-infiltrating cells which potentiates tumor eradication. Our findings present novel approach safe effective radioimmunotherapy, where sensitized LDI achieves therapeutic enhancement through precise ICD induction activation.

Language: Английский

Citations

0
Novel Intravenous Formulation for Radiosensitization in Osteosarcoma Treatment DOI Creative Commons
Haitao Zeng, Huixiong Feng, Chong Zhang

et al.

Materials Today Bio, Journal Year: 2025, Volume and Issue: 32, P. 101682 - 101682

Published: March 18, 2025

Language: Английский

Citations

0
HPV status and immunohistochemical analysis of p16, p53 and PD‑L1 expression as prognostic biomarkers in patients with squamous cell anal cancer receiving definitive radiotherapy/chemoradiotherapy DOI Open Access

Beril Balci Topuz,

Fatma Sert, Murat Sezak

et al.

Oncology Letters, Journal Year: 2024, Volume and Issue: 28(2)

Published: June 25, 2024

Anal squamous cell carcinoma (SCC) treated with definitive radiotherapy (RT)/chemoradiotherapy (CRT) has shown high success rates, yet challenges such as treatment resistance and recurrence persist. The present study aimed to investigate the associations between immunohistochemical (IHC) evaluation, response prognosis in anal SCC. A retrospective cohort analysis included 42 patients SCC at a single institution 2006 2022. Human papillomavirus (HPV) status was determined, IHC of p16, p53 PD‑L1 expression conducted using formalin‑fixed, paraffin‑embedded biopsies. complete RT/CRT observed 71.4% patients. Recurrence occurred 38.1% cases, which 7.1% had local‑regional (LRR), 14.3% distant (DR), 16.7% both LRR DR. HPV positivity (71.4%) significantly associated p16 positivity. Lack HPV‑negative status, p16‑negative increased In addition, p53‑positive LRR. positivity, defined combined positive score (CPS) ≥1% found 73.8% patients, exhibited significant CPS ≥ 1% also an Univariate revealed that age <65 years, were 5‑year overall survival (OS), while response, p53‑negative disease‑free (DFS). Multivariate identified years are independent prognostic factors for OS, DFS. conclusion, these findings suggust identification poor biomarkers diagnosis may be used guide personalized strategies, combination immunotherapy standard CRT potentially providing improved outcomes.

Language: Английский

Citations

0
Nanoparticle-Enabled In Situ Drug Potency Activation for Enhanced Tumor-Specific Therapy DOI Creative Commons
Yitian Chen, Lishan Liu, Min Li

et al.

European Journal of Pharmaceutical Sciences, Journal Year: 2024, Volume and Issue: 205, P. 106989 - 106989

Published: Dec. 14, 2024

Language: Английский

Citations

0
Metabolizable alloy clusters assemble nanoinhibitor for enhanced radiotherapy of tumor by hypoxia alleviation and intracellular PD-L1 restraint DOI Creative Commons

Guanwen Ding,

Shengnan Liu, Xiangshan Yang

et al.

Journal of Nanobiotechnology, Journal Year: 2024, Volume and Issue: 22(1)

Published: Dec. 19, 2024

Cancer radiotherapy (RT) still has limited clinical success because of the obstacles including radioresistance hypoxic tumors, high-dose X-ray–induced damage to adjacent healthy tissue, and DNA-damage repair by intracellular PD-L1 in tumor. Therefore, overcome these multifunctional core–shell BMS@Pt2Au4 nanoparticles (NPs) are prepared using nanoprecipitation followed electrostatic assembly. Pt2Au4 clusters released from NPs alleviate tumor hypoxia catalyzing decomposition endogenous H2O2 generate O2 as well enhancing X-ray deposition at site, which thereby reduce required dose. The BMS-202 molecules simultaneously blockade on cells, causing activation effector T cells inhibition repair. Consequently, based enhance expression calreticulin cancer transposition HMGB1 nucleus cytoplasm, generation reactive oxygen species (ROS), DNA breakage apoptosis vitro. rate reached 92.5% under three cycles 1-Gy irradiation vivo. In conclusion, therapeutic outcome supports high-efficiency tumors expressing PD-L1.

Language: Английский

Citations

0